May 8 2016

Title Goes Here

To achieve this, we will conduct the first extensive genomic analyses of hereditary breast and ovarian cancers from women who carry BRCA mutations. This study will involve deep whole genome sequencing of tumor and normal tissue to identify the key somatic changes in these cancers. We will further extend our analyses to conduct studies of the mechanistic dynamics of tumor evolution to understand the biology of tumor growth so that targets for potential new therapies can be developed. We will also apply, for the first time, an ultrasensitive method for quantitating circulating tumor DNA from samples derived from patients with BRCA1 and BRCA 2. This method, developed at Stanford, will detect specific “signatures” associated with BRCA1/2hereditary cancers learned from our earlier work. This interdisciplinary and collaborative work will further elucidate the understanding of BRCA mutations and apply methods that will be routinely applied clinically to detect and monitor cancers, thereby facilitating personalized cancer therapy for patients with hereditary cancers. Together with our research partners at UCSF and Dana Farber Cancer Institute, we hope to advance our abilities for the prevention, early detection, treatment and cure of hereditary cancers.

To achieve this, we will conduct the first extensive genomic analyses of hereditary breast and ovarian cancers from women who carry BRCA mutations. This study will involve deep whole genome sequencing of tumor and normal tissue to identify the key somatic changes in these cancers. We will further extend our analyses to conduct studies of the mechanistic dynamics of tumor evolution to understand the biology of tumor growth so that targets for potential new therapies can be developed. We will also apply, for the first time, an ultrasensitive method for quantitating circulating tumor DNA from samples derived from patients with BRCA1 and BRCA 2. This method, developed at Stanford, will detect specific “signatures” associated with BRCA1/2hereditary cancers learned from our earlier work. This interdisciplinary and collaborative work will further elucidate the understanding of BRCA mutations and apply methods that will be routinely applied clinically to detect and monitor cancers, thereby facilitating personalized cancer therapy for patients with hereditary cancers. Together with our research partners at UCSF and Dana Farber Cancer Institute, we hope to advance our abilities for the prevention, early detection, treatment and cure of hereditary cancers.

To achieve this, we will conduct the first extensive genomic analyses of hereditary breast and ovarian cancers from women who carry BRCA mutations. This study will involve deep whole genome sequencing of tumor and normal tissue to identify the key somatic changes in these cancers. We will further extend our analyses to conduct studies of the mechanistic dynamics of tumor evolution to understand the biology of tumor growth so that targets for potential new therapies can be developed. We will also apply, for the first time, an ultrasensitive method for quantitating circulating tumor DNA from samples derived from patients with BRCA1 and BRCA 2. This method, developed at Stanford, will detect specific “signatures” associated with BRCA1/2hereditary cancers learned from our earlier work. This interdisciplinary and collaborative work will further elucidate the understanding of BRCA mutations and apply methods that will be routinely applied clinically to detect and monitor cancers, thereby facilitating personalized cancer therapy for patients with hereditary cancers. Together with our research partners at UCSF and Dana Farber Cancer Institute, we hope to advance our abilities for the prevention, early detection, treatment and cure of hereditary cancers.